Relevant bibliographies by topics / Cushing's syndrome – Treatment

Academic literature on the topic 'Cushing's syndrome – Treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cushing's syndrome – Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cushing's syndrome – Treatment"

1

LUFT, ROLF. "The Treatment of Cushing's Syndrome." Acta Medica Scandinavica 124, no. 3 (April 24, 2009): 227–51. http://dx.doi.org/10.1111/j.0954-6820.1946.tb09204.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

SARTOR, OLIVER, and GORDON B. CUTLER. "Mifepristone: Treatment of Cushing's Syndrome." Clinical Obstetrics and Gynecology 39, no. 2 (June 1996): 506–10. http://dx.doi.org/10.1097/00003081-199606000-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

MIURA, KIYOSHI. "Medical treatment for Cushing's syndrome." Nihon Naika Gakkai Zasshi 83, no. 9 (1994): 1627–32. http://dx.doi.org/10.2169/naika.83.1627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Atkinson, A. B. "The treatment of Cushing's syndrome." Clinical Endocrinology 34, no. 6 (June 1991): 507–13. http://dx.doi.org/10.1111/j.1365-2265.1991.tb00332.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Terzolo, Massimo, Silvia Bovio, Anna Pia, Giangiacomo Osella, Giorgio Borretta, Alberto Angeli, and Giuseppe Reimondo. "Subclinical Cushing's syndrome." Arquivos Brasileiros de Endocrinologia & Metabologia 51, no. 8 (November 2007): 1272–79. http://dx.doi.org/10.1590/s0004-27302007000800013.

Full text
Abstract:
Subclinical Cushing's syndrome (CS) is attracting increasing interest since the serendipitous discovery of an adrenal mass has become a rather frequent event owing to the routine use of sophisticated radiologic techniques. Cortical adenoma is the most frequent type of adrenal incidentaloma accounting for approximately 50% of cases in surgical series and even greater shares in medical series. Incidentally discovered adrenal adenomas may secrete cortisol in an autonomous manner that is not fully restrained by pituitary feedback, in 5 to 20% of cases depending on study protocols and diagnostic criteria. The criteria for qualifying subclinical cortisol excess are controversial and presently there is no consensus on a gold standard for the diagnosis of this condition. An increased frequency of hypertension, central obesity, impaired glucose tolerance, diabetes and hyperlipemia has been described in patients with subclinical CS; however, there is still no clear demonstration of the long-term complications of this condition whose management remains largely empirical. Either adrenalectomy or careful observation associated with treatment of the metabolic syndrome have been suggested as treatment options.
APA, Harvard, Vancouver, ISO, and other styles
6

Shukla, Lekhansh. "Cushing's Syndrome and Treatment-Resistant Depression." Indian Journal of Psychological Medicine 39, no. 2 (March 2017): 213–14. http://dx.doi.org/10.4103/0253-7176.203114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

MILLER, JEFFREY W., and LAWRENCE CRAPO. "The Medical Treatment of Cushing's Syndrome." Endocrine Reviews 14, no. 4 (August 1993): 443–58. http://dx.doi.org/10.1210/edrv-14-4-443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rao, D. "Reversible Cardiomyopathy in Cushing Syndrome-A Rare Presentation." Indian Journal of Cardiovascular Disease in Women WINCARS 01, no. 03 (September 2016): 035–38. http://dx.doi.org/10.1055/s-0038-1656478.

Full text
Abstract:
AbstractCushing syndrome (CS) is the result of extended exposure to excessive glucocorticoids from endogenous or exogenous sources. Cushing's syndrome (CS) is associated with reduced life quality and increased mortality, mostly due to cardiovascular disease. We report the case of a 26-year-old female patient who presented with heart failure who was found to have Cushing syndrome and recovered after supportive treatment.
APA, Harvard, Vancouver, ISO, and other styles
9

Pilmis, Benoit, Hélène Coignard-Biehler, Vincent Jullien, Olivier Hermine, Philippe Touraine, Marc Lecuit, and Olivier Lortholary. "Iatrogenic Cushing's Syndrome Induced by Posaconazole." Antimicrobial Agents and Chemotherapy 57, no. 11 (August 26, 2013): 5727–28. http://dx.doi.org/10.1128/aac.00416-13.

Full text
Abstract:
ABSTRACTIatrogenic Cushing's syndrome is an undesirable outcome of glucocorticoids treatment. It can be increased by pharmacologic interactions. Glucocorticoid therapy, given in association with ritonavir, and some azole treatments are causes of iatrogenic Cushing's syndrome. We present a patient with common-variable immunodeficiency who received 7 years of itraconazole therapy for bronchial colonization withAspergillusin combination with inhaled fluticasone without any Cushingoid symptoms. After a switch to posaconazole, the patient developed Cushingoid symptoms.
APA, Harvard, Vancouver, ISO, and other styles
10

B. N., Anil Kumar, and Sandeep Grover. "Cushing's Syndrome Masquerading as Treatment Resistant Depression." Indian Journal of Psychological Medicine 38, no. 3 (May 2016): 246–48. http://dx.doi.org/10.4103/0253-7176.183095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cushing's syndrome – Treatment"

1

Emmerich, Juliette [Verfasser], and Rolf W. [Akademischer Betreuer] Hartmann. "Lead optimization of highly potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome and chronic wounds / Juliette Emmerich ; Betreuer: Rolf W. Hartmann." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2018. http://d-nb.info/1155164695/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Emmerich, Juliette Verfasser], and Rolf W. [Akademischer Betreuer] [Hartmann. "Lead optimization of highly potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome and chronic wounds / Juliette Emmerich ; Betreuer: Rolf W. Hartmann." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2018. http://d-nb.info/1155164695/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Burt, Morton Garth St Vincent's Clinical School UNSW. "Mechanisms underlying glucocorticoid-induced protein wasting and potential treatment with anabolic hormoness." 2007. http://handle.unsw.edu.au/1959.4/41293.

Full text
Abstract:
Protein wasting is a complication of glucocorticoid (GC) therapy. It causes substantial morbidity and there is no treatment. This thesis investigates the metabolic mechanisms underlying GC-induced protein wasting and the potential for anabolic hormones to reverse protein loss. The models of GC excess were Cushing's syndrome and GC therapy. Whole body protein metabolism was assessed using the leucine turnover technique and body composition by dual-energy X-ray absorptiometry to estimate lean body mass (LBM) and fat mass (FM). As previous studies demonstrated that LBM and FM influenced rates of protein metabolism, the magnitude of body compositional abnormality in Cushing's syndrome was determined. After accounting for the greater FM (30%) and lesser LBM (15%), protein metabolism in Cushing's syndrome was characterised by a significant increase in protein oxidation, an abnormality that leads to irreversible protein loss. Successful treatment of Cushing's syndrome normalised protein oxidation. Studies of the acute and chronic effects of therapeutic GCs revealed a time-dependent effect on protein metabolism. GCs acutely increased protein oxidation. However, the rate of protein oxidation during chronic therapy at a similar dose was not significantly different to untreated control subjects. This time-dependent change suggests that GC-induced stimulation of protein oxidation does not persist and could represent a metabolic adaptation to limit protein loss. This finding contrasts with that in Cushing's syndrome, where protein oxidation is persistently elevated. This difference may represent a dose effect. Studies in GH-deficient subjects revealed that GH induced a fall in protein oxidation that was significantly correlated with a subsequent gain in LBM. This suggests that the anabolic potential of a therapeutic substance can be predicted by its ability to suppress protein oxidation acutely. Finally, the potential for GH and androgens to reverse the metabolic effects of GCs was assessed. A preliminary study in GC users revealed that a GH dose of 0.8 mg/d was effective in reducing protein oxidation. In a subsequent study, the GH-induced reduction in protein oxidation in women on GCs was enhanced by combined treatment with dehydroepiandrosterone, an androgen. In summary, GCs induce protein loss by stimulating protein oxidation. GH reverses this effect and this action is enhanced by coadministration of androgens. GH and androgens may be used therapeutically to prevent protein loss induced by GCs.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cushing's syndrome – Treatment"

1

service), SpringerLink (Online, ed. Cushing's Syndrome: Pathophysiology, Diagnosis and Treatment. Totowa, NJ: Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Energy. RU 486: The import ban and its effect on medical research : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred First Congress, second session, Washington, DC, November 19, 1990. Washington: U.S. G.P.O., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

United, States Congress House Committee on Small Business Subcommittee on Regulation Business Opportunities and Energy. RU 486: The import ban and its effect on medical research : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred First Congress, second session, Washington, DC, November 19, 1990. Washington: U.S. G.P.O., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bronstein, Marcello D. Cushing's Syndrome: Pathophysiology, Diagnosis and Treatment. Humana, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

RU 486: The import ban and its effect on medical research : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred First Congress, second session, Washington, DC, November 19, 1990. Washington: U.S. G.P.O., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hardacker, Doris M. Cushing’s Disease. Edited by Matthew D. McEvoy and Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0029.

Full text
Abstract:
Cushing’s syndrome is caused by adrenocorticotropic hormone (ACTH)-secreting or cortisol-secreting tumors. In most cases, the hypercortisolism is caused by an ACTH-secreting tumor of the pituitary. An excess of circulating cortisol adversely affects all major organ systems, including the cardiovascular system and therefore produces a wide range of clinical features. Perioperative morbidity and mortality will largely be determined by the magnitude of cardiac dysfunction encountered. Successful perioperative management depends on a thorough preoperative assessment of affected organs, comprehensive intraoperative monitoring, and an understanding of potential interactions with anesthetic drugs. Surgical reselection is most often the definitive treatment for this syndrome, however there are pharmacologic interventions that can be undertaken when necessary.
APA, Harvard, Vancouver, ISO, and other styles
7

Lovett, Alexandra, and Whitney W. Woodmansee. A Woman with Weight Gain and Fatigue. Edited by Angela O’Neal. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190609917.003.0011.

Full text
Abstract:
Cushing’s syndrome is a descriptive term of a syndrome secondary to elevated levels of steroids or cortisol, while Cushing’s disease is hypercortisolemia that results from an adrenocorticotropic (ACTH)-secreting pituitary adenoma. Patients will present with cushingoid features on physical examination and can be myopathic with proximal rather than distal muscle weakness. Diagnosis can be obtained by multiple avenues including but not limited to checking 24 hour urine cortisol, a dexamethasone suppression test, checking ACTH levels, a CRH (corticotrophin-releasing hormone) stimulation test, and inferior petrosal sinus sampling (IPSS). Once Cushing’s disease is confirmed, treatment is via transsphenoidal resection of the pituitary adenoma.
APA, Harvard, Vancouver, ISO, and other styles
8

Bagul, A., and Saba Balasubramanian. Treatment of adrenal tumours. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0095.

Full text
Abstract:
The incidence of adrenal tumours has risen dramatically over the last two decades, mainly due to the incidental detection of adrenal lesions on cross sectional imaging performed for other diseases. These ‘incidentalomas’ are commoner than the well-known hormonal syndromes such as Cushing’s, Conn’s, and pheochromocytoma. Suspicion or detection of an adrenal tumour should result in a detailed biochemical and structural evaluation in a multidisciplinary setting. The relatively low incidence of adrenal disease coupled with the varied nature of presentation makes concentration of volume and encouragement of expertise difficult in this area; however, these are important as it correlates directly with outcome.
APA, Harvard, Vancouver, ISO, and other styles
9

Blanshard, Hannah. Endocrine and metabolic disease. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198719410.003.0008.

Full text
Abstract:
This chapter describes the anaesthetic management of the patient with endocrine and metabolic disease. Topics covered include diabetes mellitus, thyroid and parathyroid disease, acromegaly, adrenocortical disease, steroid therapy, Cushing’s and Conn’s syndromes, apudoma (including phaeochromocytoma), and abnormalities of sodium and potassium. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described. The perioperative management of the diabetic patient is discussed in detail, including insulin and oral hypoglycaemic therapy. Perioperative steroid management is described.
APA, Harvard, Vancouver, ISO, and other styles
10

Blanshard, Hannah. Endocrine and metabolic disease. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198719410.003.0008_update_001.

Full text
Abstract:
This chapter describes the anaesthetic management of the patient with endocrine and metabolic disease. Topics covered include diabetes mellitus, thyroid and parathyroid disease, acromegaly, adrenocortical disease, steroid therapy, Cushing’s and Conn’s syndromes, apudoma (including phaeochromocytoma), and abnormalities of sodium and potassium. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described. The perioperative management of the diabetic patient is discussed in detail, including insulin and oral hypoglycaemic therapy. Perioperative steroid management is described.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cushing's syndrome – Treatment"

1

Young, William F., and Geoffrey B. Thompson. "Adrenal-Directed Treatment Options for Cushing’s Disease." In Cushing's Syndrome, 131–37. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-449-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alexandraki, Krystallenia I., Andrea M. Isidori, and Ashley B. Grossman. "ACTH-Dependent Cushing Syndrome: Clinical and Diagnostic Aspects, and Treatment Approaches for Ectopic Cushing’s Syndrome." In Cushing's Syndrome, 163–76. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-449-4_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alexandraki, Krystallenia I. "Emergency Treatment of Florid Cushing's Syndrome." In Endocrine and Metabolic Medical Emergencies: A Clinician's Guide, 159–64. 2055 L Street, NW, Suite 600, Washington, DC 20036 www.endo-society.org: The Endocrine Society, 2014. http://dx.doi.org/10.1210/eme.9781936704811.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cizza, Giovanni, and George P. Chrousos. "Adrenocorticotrophic hormone-dependent Cushing’s syndrome." In Cancer Treatment and Research, 25–40. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-6355-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bhansali, Anil, and Yashpal Gogate. "Cushing’s Syndrome: Diagnosis and Treatment." In Clinical Rounds in Endocrinology, 95–124. New Delhi: Springer India, 2015. http://dx.doi.org/10.1007/978-81-322-2398-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Neychev, Vladimir. "Cushing Syndrome: Presentation, Diagnosis, and Treatment, Including Subclinical Cushing Syndrome." In Management of Adrenal Masses in Children and Adults, 159–78. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-44136-8_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Damian, Morris, and Ashley Grossman. "Cushing’s Syndrome - The Diagnosis and Differential Diagnosis." In The Acth Axis: Pathogenesis, Diagnosis and Treatment, 229–57. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0501-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bourdeau, Isabelle, Nina N’Diaye, Hortensia Mircescu, Johanne Tremblay, Pavel Hamet, and Ander Lacroix. "Cushing’s Syndrome due to Aberrant Adrenal Hormone Receptors." In The Acth Axis: Pathogenesis, Diagnosis and Treatment, 207–28. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0501-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nieman, Lynnette K., George P. Chrousos, Charles Kellner, Irving M. Spitz, Bruce C. Nisula, Gordon B. Cutler, George R. Merriam, C. Wayne Bardin, and D. Lynn Loriaux. "Use of the Glucocorticoid Antagonist RU 486 in the Treatment of Cushing’s Syndrome." In The Antiprogestin Steroid RU 486 and Human Fertility Control, 339–45. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-1242-0_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Raychaudhuri, Moutusi. "Cushing's Syndrome." In Treatment and Prognosis in Pediatrics, 282. Jaypee Brothers Medical Publishers (P) Ltd., 2013. http://dx.doi.org/10.5005/jp/books/11937_86.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cushing's syndrome – Treatment"

1

Hendarto, Hari. "Iatrogenic Cushing's syndrome caused by treatment with traditional herbal medicine, a case report." In 1st International Integrative Conference on Health, Life and Social Sciences (ICHLaS 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/ichlas-17.2017.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Власюк, Ангелина Александровна, Александр Александрович Федорцов, Людмила Валентиновна Васильева, and Дмитрий Андреевич Малюков. "DRUG-INDUCED ITSENKO-CUSHING SYNDROME AS AN IMPORTANT PROBLEM OF MODERN MEDICINE." In Психология. Спорт. Здравоохранение: сборник избранных статей по материалам Международной научной конференции (Санкт-Петербург, Февраль 2021). Crossref, 2021. http://dx.doi.org/10.37539/psm295.2021.32.91.003.

Full text
Abstract:
В данной статье представлена информация о медикаментозном синдроме Иценко-Кушинга, развивающегося у пациентов вследствие употребления глюкокортикойдов при различных заболеваниях, а также зависимость развития осложнений от методик получаемого лечения. The article presents information about the Itsenko-Cushing drug syndrome, which develops in patients as a result of the use of glucocorticoids for various diseases, as well as the dependence of the development of complications on the received treatment methods.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cushing's syndrome – Treatment' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography